| Literature DB >> 20510764 |
David R Carr1, Michael P Heffernan.
Abstract
Since its approval in 1997 by the US Food and Drug Administration, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many published reports have suggested rituximab's efficacy in several inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, side-effect profile, and the current literature for various off-label uses of this CD20+ B-cell antagonist, rituximab. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20510764 DOI： 10.1016/j.det.2010.03.002
Source DB: PubMed Journal: Dermatol Clin ISSN： 0733-8635 Impact factor: 3.478